Pure ovarian choriocarcinomas are extremely rare and aggressive tumors which are gestational or nongestational in origin. Due to the rarity of the tumor, there is a lack of information on the clinicopathologic features, diagnosis, and treatment. We report a case of a pure ovarian choriocarcinoma, likely of nongestational origin, treated by cytoreductive surgery in combination with postoperative chemotherapy. The patient was free of disease after a 12month followup.
INTRODUCTION
Pure ovarian choriocarcinomas are extremely rare malignan cies which are of gestational or nongestational in origin. The gestational type may arise from an ectopic ovarian pre gnancy or present as a metastasis from a uterine or tubal choriocarcinoma, while the nongestational type is a rare germ cell tumor with trophoblastic differentiation. The esti mated incidence of gestational ovarian choriocarcinomas is 1 in 369 million pregnancies [1] . Nongestational ovarian choriocarcinomas account ≤0.6% of all ovarian neoplasms; the pure type is extremely uncommon [2] . Due to the rarity of pure ovarian choriocarcinomas, information on the clinicopathologic features, diagnosis, and therapeutic options is limited. Herein we present a case of a pure ovarian choriocarcinoma, likely of nongestational origin, and discuss the diagnosis and treatment together with a brief review of the literature.
CASE REPORT
A 48yearold woman was admitted to our department with a 6month history of irregular vaginal bleeding and a 1month history of a palpable abdominal mass. She had a nor mal vaginal delivery at 26 years of age and had no recent history of normal pregnancies, molar gestations, or abortions. The physical examination revealed abdominal tenderness and a fixed mass arising from the pelvis to 3 cm below the um bilicus. Ultrasound showed a 15cm solid mass posterior to the uterus, and consistent with an ovarian tumor. The serum levels of tumor markers, with normal values in parentheses, were as follows: βhuman chorionic gonadotropin (hCG), 7,664.3 mIU/mL (<5.0); CA125, 217.3 U/mL (<35); CA199, 18.6 U/mL (<30); alpha fetoprotein (AFP), 1.9 ng/mL (<20); and car cinoembryonic antigen (CEA), 2.5 ng/mL (<5). There was no evi dence of metastasis to other organs.
After written informed consent was obtained, an exploratory laparotomy was undertaken for a suspected ovarian tumor. Intraoperatively, a darkred, soft, friable, 18×15×14 cm mass had replaced the right ovary, which was densely adherent to the colon, rectum, appendix, and posterior surface of the uterus. The left ovary and fallopian tube were normal in appearance. There was no ascites within the peritoneal cavity. Peritoneal washings were obtained for cytology. Cytoreductive Pathology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China surgery, including a subextensive total hysterectomy, bilateral salpingooophorectomy, pelvic lymphadenectomy, paraaortic lymph node sampling, omentectomy, appendectomy, and peritoneal biopsies was performed. Optimal debulking was achieved with no macroscopic residual tumor.
Microscopically, the tumor was confirmed to be a pure choriocarcinoma with widespread necrosis (Fig. 1) . The appendi ceal serosa and peritoneum were identified with tumor invasion. The uterus, left ovary, left fallopian tube, omentum and all of the extirpated lymph nodes were nega tive for malig nancy. Immunohistochemically, the tumor was positive for βhCG ( Fig. 2A ) and weakly positive for placental like alkaline phosphatase (PLAP) (Fig. 2B ). Eighty percent of the tumor cells were strongly positive for Ki67. 3) . The patient did well after surgery and tolerated 6 cycles of chemotherapy without problems and without evidence of disease after a 12month followup.
DISCUSSION
Pure ovarian choriocarcinomas are rare, but aggressive tu 
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mors that pose diagnostic and therapeutic challenges. The preoperative diagnosis of pure ovarian choriocarcinomas is very difficult, especially for patients in the reproductive age due to the nonspecific clinical symptoms which can mimic other more common diseases. In the presence of an adnexal mass with an increased serum βhCG level and irregular vaginal bleeding, pure ovarian choriocarcinomas in the childbearing age can be easily mistaken for an ectopic pregnancy preoperatively [3, 4] . Some authors have reported the preoperative diagnosis of pure ovarian choriocarcinomas based on fine needle aspiration cytology [5] or imaging and biologic findings [6] . Confirmation of the diagnosis still relies on the histopathologic findings. Indeed, the presence of malignant cytotrophoblasts and syncytiotrophoblasts, immunohistochemical staining with βhCG, and placental lactogen are diagnostic. There are no distinctive ultrastructural or immunohistochemical differences between gestational and nongestational choriocarcinomas. Thus, to distinguish a gestational ovarian choriocarcinoma from a pure non gestational ovarian choriocarcinoma based on conventional histopathologic studies is not currently possible in the repro ductive age group. Molecular genetic analysis is a reliable method for identifying the genetic origin of pure ovarian choriocarcinomas [710] . However, since such techniques are always expensive and not generally available in all medical centers, the application is limited. For this very reason, we could not perform molecular genetic analysis on the tumor from our patient. In light of the long duration (22 years) from the antecendent pregnancy, the absence of intrauterine tro phoblastic disease, and the relatively low βhCG level, we 138 www.ejgo.org suggest that our patient had a pure nongestational ovarian choriocarcinoma.
We have reviewed the previously reported cases of pure ovarian choriocarcinoma and summarized the details of these cases including βhCG level, operation procedures, chemotherapy and outcome. Since Goswami et al. [11] made a detailed summary and analysis about 30 cases of pure nongestational choriocarcinoma in 2001, we only present cases not mentioned by Goswami et al. [11] or reported after Goswami's study in our article (Table 1) . Accor ding to the previous reports, it seems that pure ovarian chorio carcinoma responds well to the combination of surgical ablation and postoperative chemotherapy. To date, no definitive treatment modality has been established for pure ovarian choriocarcinomas due to the low incidence. Thus, pure ovarian choriocarcinomas are generally treated by the same protocols used for ovarian germcell tumors and gestational trophoblastic disease. In the current case, the treatment included cytoreductive surgery followed by post operative chemotherapy. Optimal cytoreductive surgery was indispensible in our patient, as demonstrated by the dra matic decline in the serum βhCG level postoperatively. There is no consensus on the optimal chemotherapy follow ing surgery. Nongestational ovarian choriocarcinoma has been found to have a worse prognosis and requires more aggressive chemotherapy compared with gestational ovarian choriocarcinoma. Gestational choriocarcinoma usually responds well to methotrexatebased chemotherapy; however, nongestational choriocarcinoma may be resistant to this therapy [11] . Because nongestational choriocarcinoma is considered as a germ cell tumor differentiating to tropho blastic components, a germ cell tumor treatment protocol may be effective [3, 21] . BEP chemotherapy is the current regi men for germ cell tumors of the ovary [23] . Thus, our patient underwent BEP chemotherapy for a presumed primary pure nongestational choriocarcinoma. The patient had a good response to the BEP regimen with a satisfactory decrease in the serum βhCG level. There was no evidence of recurrence or metastasis after a 12month followup. Our case provides evidence that cytoreductive surgery in combination with post operative chemotherapy may be an effective therapeutic strategy for pure ovarian choriocarcinomas. Considering that pure ovarian choriocarcinoma is aggressive with a high risk of metastasis, close followup with serum βhCG and imaging examinations is essential.
